Penn's Renal-Electrolyte and Hypertension Division

Penn's active research and clinical trials provide additional resources for kidney transplant patients. Take a look at the current kidney transplantation clinical trials being performed at Penn.

Project LIFT: Lifestyle Intervention to promote Fitness in Transplantation

Principal Investigator: Peter Reese, MD, MSCE

Type Of Study: Pilot, Randomized Controlled Trial

Brief Description Of Study: Project LIFT is a remotely-monitored home exercise program that tests the use of wearable devices, financial incentives, and health questions to promote healthy behavior.

Detailed Study Description: Among kidney (KT) and liver transplant (LT) recipients, weight gain and obesity is associated with poor graft function. Yet, within a year of transplantation, habituation to a sedentary lifestyle, changes in metabolism, and immunosuppression drugs contribute to an average 4-10 kg weight gain for recipients. Recent innovations in wearable devices technology can passively monitor an individual’s physical activity.  Additionally, incentives and health questions designed using insights from behavioral economics have been shown to motivate device engagement and improvements in health behaviors. A remotely-monitored exercise program could improve behavior change and take advantage of the high motivation for improving health in this population.

General Inclusion Criteria: Adult liver or kidney transplant recipients within 2 – 24 months after of transplantation. They have to have a smartphone and be willing to receive text messages.

General Exclusion Criteria:

  1. Inability to provide informed consent; 
  2. Does not have daily access to a smartphone compatible with the wearable device
  3. Unable or unwilling to complete the baseline measurements and survey or return to perform the exit interview and weigh-in
  4. Already enrolled in an financial incentive-based exercise program using a wearable device
  5. Use of a wearable accelerometer or pedometer outside of the study protocol
  6. Any other medical conditions that would prohibit participation in a physical activity program
  7. Severe vision, hearing, or mobility impairment precluding participation

Contact Information:
Dr. Peter Reese
Principal Investigator
Peter.Reese@uphs.upenn.edu

Adam Mussel
Project Manager
Adam.Mussell@uphs.upenn.edu

Sakshum Chadha
Clinical Research Coordinator
Sakshum.Chadha@uphs.upenn.edu
215-746-0355

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors (HCV)

Co-Principal Investigators: David Goldberg, MD, MSCE and Peter Reese, MD, MSCE

Sponsor: Merck

This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant wait list, who will then be treated with Zepatier after the single kidney transplantation.

Research coordinator: Anna Sicilia, anna.sicilia@uphs.upenn.edu

PERT Study: The Use of Peri-operative Intravenous Estrogen for the Mitigation of Ischemia Reperfusion Injury in the Setting of Renal Transplantation

Principal Investigator: Matthew Levine, MD, PhD

The purpose of this study is to see if giving intravenous (IV) estrogen at the time of kidney transplant will help the kidney work properly after it is transplanted. Sometimes after a kidney is transplanted, the kidney does not work as it should right away. When this happens, patients typically require dialysis treatments within the first week after transplant.

When the transplanted kidney does not work right away, there can be increased medical costs, increased length of hospital stay and decreased graft (kidney) survival. Currently there are no preventative measures or treatments though dialysis is used until recovery of kidney function occurs. Some research studies in mice have shown a more positive outcome in female compared to male mice. Research in this area has focused on hormonal effects of estrogen and testosterone. This is a randomized trial where participating subjects will receive either three doses of intravenous estrogen or an intravenous placebo during their hospital stay.

Contact: Mary Shaw, BBA, RN at 215-615-0528 or mary.shaw@uphs.upenn.edu

Share This Page: